Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,481 to 3,500 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: serious adverse events | 251 of 998 262 of 1,002 | -1.0 points -4.8 to 2.8 | 2,000 | NCT06025695 Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks |
| Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death | 351 of 998 347 of 1,001 | 0.5 points -3.7 to 4.7 | 1,999 | NCT00071032 Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease |
| Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Mortality at 60 Days | 76 of 998 66 of 1,001 | 1.0 points -1.2 to 3.3 | 1,999 | NCT00071032 Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease |
| Male Group vs Female Group: Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender) | 775 of 787 1,202 of 1,212 | -0.7 points -1.9 to 0.2 | 1,999 | NCT02014519 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary |
| Female Group vs Male Group: Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Gender) | 160 of 1,212 135 of 787 | -4.0 points -7.3 to -0.8 | 1,999 | NCT02014519 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary |
| Female Group vs Male Group: Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Gender) | 10 of 1,212 12 of 787 | -0.7 points -1.9 to 0.2 | 1,999 | NCT02014519 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary |
| Female Group vs Male Group: Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender) | 1,052 of 1,212 652 of 787 | 4.0 points 0.8 to 7.3 | 1,999 | NCT02014519 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary |
| Female Group vs Male Group: Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Gender) | 0 of 1,212 2 of 787 | -0.3 points -0.9 to 0.1 | 1,999 | NCT02014519 A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary |
| Standard WBI vs WBI, Trastuzumab: deaths from any cause | 11 of 1,005 10 of 993 | 0.1 points -0.9 to 1.1 | 1,998 | NCT00769379 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy |
| Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Disposition Status (i.e., Nursing Home Placement) | 137 of 996 161 of 1,001 | -2.3 points -5.5 to 0.8 | 1,997 | NCT00071032 Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease |
| Ferumoxytol vs Ferric Carboxymaltose (FCM): serious adverse events | 36 of 997 35 of 1,000 | 0.1 points -1.5 to 1.8 | 1,997 | NCT02694978 A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) |
| Direct Admission vs ED Admission: Number of Participants With Clinical Deterioration | 1 of 145 15 of 1,852 | -0.1 points -0.9 to 3.0 | 1,997 | NCT04192799 Comparative Effectiveness of Direct Admission & Admission Through Emergency Departments for Children |
| ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: Number of Participants Who Experienced an Adverse Event (AE) | 530 of 1,504 140 of 492 | 6.8 points 2.0 to 11.3 | 1,996 | NCT02616146 Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062) |
| ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: Number of Participants Who Discontinued Treatment Due to an AE | 61 of 1,504 23 of 492 | -0.6 points -3.0 to 1.3 | 1,996 | NCT02616146 Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062) |
| ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: serious adverse events | 8 of 1,504 3 of 492 | -0.1 points -1.3 to 0.6 | 1,996 | NCT02616146 Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062) |
| Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Mortality at 30 Days | 52 of 995 43 of 1,000 | 0.9 points -1.0 to 2.8 | 1,995 | NCT00071032 Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease |
| Dabigatran 220mg vs Enoxaparin: Number of Participants Who Died During Treatment Period | 0 of 1,001 1 of 992 | -0.1 points -0.6 to 0.3 | 1,993 | NCT00657150 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty |
| Dabigatran 220mg vs Enoxaparin: Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period | 0 of 1,001 4 of 992 | -0.4 points -1.0 to 0.1 | 1,993 | NCT00657150 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty |
| Dabigatran 220mg vs Enoxaparin: Number of Participants With Pulmonary Embolism During Treatment Period | 1 of 1,001 2 of 992 | -0.1 points -0.6 to 0.4 | 1,993 | NCT00657150 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty |
| Montelukast 10 mg vs Placebo: serious adverse events | 4 of 1,002 1 of 990 | 0.3 points -0.2 to 0.9 | 1,992 | NCT00092118 The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=175"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=175
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT06025695-sae",
"title": "Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: serious adverse events",
"summary": "251 of 998 against 262 of 1002; risk difference -1.0 points, 95% interval -4.8 to 2.8; NCT06025695, Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks",
"record": "/library/comparisons/NCT06025695-sae",
"nct_id": "NCT06025695",
"kind": "serious-adverse-events",
"participants": 2000,
"risk_difference": {
"value": -0.009974039896159637,
"lower": -0.0481980603663736,
"upper": 0.028295107923809897
},
"group_1": "251 of 998",
"group_2": "262 of 1,002",
"difference": "-1.0 points",
"interval": "-4.8 to 2.8",
"trial_title": "Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks"
},
{
"id": "NCT00071032-c7b04be3",
"title": "Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death",
"summary": "351 of 998 against 347 of 1001; risk difference 0.5 points, 95% interval -3.7 to 4.7; NCT00071032, Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease",
"record": "/library/comparisons/NCT00071032-c7b04be3",
"nct_id": "NCT00071032",
"kind": "outcome",
"participants": 1999,
"risk_difference": {
"value": 0.005050060160280645,
"lower": -0.03669107442293068,
"upper": 0.046770243504720005
},
"group_1": "351 of 998",
"group_2": "347 of 1,001",
"difference": "0.5 points",
"interval": "-3.7 to 4.7",
"trial_title": "Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=176",
"request_id": "W9bkI8mFFnv8dLfY"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant